• 1
    Kemeny NE, Ron IG. Liver metastases. Curr Treat Options Gastroenterol 1999; 2: 549572.
  • 2
    Semelka RC, Cance WG, Marcos HB, Mauro MA. Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999; 213: 8691.
  • 3
    Peterson MS, Baron RL, Dodd III GD, Zajko AJ, Oliver III JH, Miller WJ, Carr BI, Bron KM, Campbell WL, Sammon JK. Hepatic parenchymal perfusion defects detected with CTAP: imaging–pathologic correlation. Radiology 1992; 185: 149155.
  • 4
    Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, Chapman WC, Pinson CW. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171: 2126.
  • 5
    Semelka RC, Martin DR, Balci C, Lance T. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001; 13: 397401.
  • 6
    Martin DR, Semelka RC. Imaging of benign and malignant focal liver lesions. Magn Reson Imaging Clin N Am 2001; 9: 785802.
  • 7
    Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver. Am J Surg 1999; 65: 11831185.
  • 8
    Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38: 11961201.
  • 9
    Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun 2000; 21: 793797.
  • 10
    Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371377.
  • 11
    Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996; 200: 785792.
  • 12
    Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178: 282287.
  • 13
    Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evalu ation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000; 174: 10051008.
  • 14
    Wiesner W, Engel H, von Schulthess GK, Krestin GP, Bicik I. FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive hurthle cell tumor of the thyroid. Eur Radiol 1999; 9: 975978.
  • 15
    Siegel BA, Adler LP, Wahl RL. FDG positron emission tomography detection of pelvic nodal metastases in gynecologic cancer. AJR Am J Roentgenol 2002; 178: 762764.
  • 16
    William AD, Cousins C, Soutter WP, et al. Detection of pelvic lymph node metastases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography. AJR Am J Roentgenol 2001; 177: 343348.